Replication proteins and human disease

Cold Spring Harbor Perspectives in Biology

Volumn 6, Issue 1, 2014, Pages

  Jackson, Andrew P ^a   Laskey, Ronald A ^b   Coleman, Nicholas ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE GAMMA;

ARTICLE; DNA REPLICATION; GENETIC DISORDER; GENETICS; HUMAN; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CELL CYCLE PROTEINS; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; GENETIC DISEASES, INBORN; HUMANS; MUTATION; NEOPLASMS;

EID: 84891636530     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a013060     Document Type: Article

References (86)

1. Amato MM, Monheit B, Shore JW. 2006. Ptosis surgery. In Duane's opthalmology (ed. Tasman W, Jaeger EA), Chap. 78, Fig. 6. Lippincott Williams and Wilkins, London.
2. Bachrati CZ, Hickson ID. 2008. RecQ helicases: Guardian angels of the DNA replication fork. Chromosoma 117: 219-233.
3. Baldwin P, Laskey R, Coleman N. 2003. Translational approaches to improving cervical screening. Nat Rev Cancer 3: 217-226.
4. Bicknell LS, Bongers EM, Leitch A, Brown S, Schoots J, Harley ME, Aftimos S, Al-Aama JY, Bober M, Brown PA, et al. 2011a. Mutations in the pre-replication complex cause Meier-Gorlin syndrome. Nat Genet 43: 356-359.
5. Bicknell LS, Walker S, Klingseisen A, Stiff T, Leitch A, Kerzendorfer C, Martin CA, Yeyati P, Al Sanna N, Bober M, et al. 2011b. Mutations in ORC1, encoding the largest subunit of the origin recognition complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome. Nat Genet 43: 350-355.
6. Bloom D. 1954. Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity. AMA Am J Dis Child 88: 754-758.
7. Bongers EM, Opitz JM, Fryer A, Sarda P, Hennekam RC, Hall BD, Superneau DW, Harbison M, Poss A, van Bokhoven H, et al. 2001. Meier-Gorlin syndrome: Report of eight additional cases and review. AmJ Med Genet 102: 115-124.
8. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, Chretien D, de Lonlay P, Paquis-Flucklinger V, Arakawa H, et al. 2007. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 39: 776-780.
9. Brown CA, Bogers J, Sahebali S, Depuydt CE, De Prins F, Malinowski DP. 2012. Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs. J Oncol 2012: 289315.
10. Celis JE, Celis A. 1985. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci 82: 3262-3266.
11. Chatrath P, Scott IS, Morris LS, Davies RJ, Bird K, Vowler SL, Grant JW, Saeed IT, Howard D, Laskey RA, et al. 2003. Aberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 89: 1048-1054.
12. Copeland WC. 2010. The mitochondrial DNA polymerase in health and disease. Subcell Biochem 50: 211-222.
13. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey RA, Miller R, Coleman N. 2002. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359: 1917-1919.
14. Davies RJ, Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ, Miller R, Coleman N. 2004. Increased expression of minichromosome maintenance protein 2 in active inflammatory bowel disease. Colorectal Dis 6: 103-110.
15. Davies RJ, Miller R, Coleman N. 2005. Colorectal cancer screening: Prospects for molecular stool analysis. Nat Rev Cancer 5: 199-209.
16. de Munnik SA, Bicknell LS, Aftimos S, Al-Aama JY, van Bever Y, Bober MB, Clayton-Smith J, Edrees AY, Feingold M, Fryer A, et al. 2012. Meier-Gorlin syndrome genotype-phenotype studies: 35 individuals with prereplication complex gene mutations and 10 without molecular diagnosis. Eur J Hum Genet 20: 598-606.
17. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. 2011. BD-ProExC as adjunct molecular marker for improved detection of CIN2{thorn} after HPV primary screening. Cancer Epidemiol Biomarkers Prev 20: 628-637.
18. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH. 2005. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11: 2510-2517.
19. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N. 1999. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5: 2121-2132.
20. German J. 1969. Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients. AmJHum Genet 21: 196-227.
21. German J. 1997. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 93: 100-106.
22. German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA. 2007. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 28: 743-753.
23. Gineau L, Cognet C, Kara N, Lach FP, Dunne J, Veturi U, Picard C, Trouillet C, Eidenschenk C, Aoufouchi S, et al. 2012. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 122: 821-832.
24. Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA, Coleman N. 2003. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21: 4306-4313.
25. Gonzalez MA, Tachibana KK, Chin S-F, Callagy G, Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman N. 2004. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204: 121-130.
26. Gonzalez MA, Tachibana KK, Laskey RA, Coleman N. 2005. Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 5: 135-141.
27. Gorlin RJ, Cervenka J, Moller K, Horrobin M, Witkop CJ Jr. 1975. Malformation syndromes. A selected miscellany. Birth Defects Orig Artic Ser 11: 39-50.
28. Guernsey DL, Matsuoka M, Jiang H, Evans S, Macgillivray C, Nightingale M, Perry S, Ferguson M, LeBlanc M, Paquette J, et al. 2011. Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome. Nat Genet 43: 360-364.
29. Harada H, Nakagawa H, Takaoka M, Lee J, Herlyn M, Diehl JA, Rustgi AK. 2008. Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle 7: 3534-3538.
30. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, Ito H. 2004. MCM2 and Ki-67 expression in human lung adenocarcinoma: Prognostic implications. Pathobiology 71: 193-200.
31. Hiraiwa A, Fujita M, Adachi A, Ono H, Nagasaka T, Matsumoto Y, Ohashi M, Tomita Y, Ishibashi M. 1998. Specific distribution patterns of hCDC47 expression in cutaneous diseases. J Cutan Pathol 25: 285-290.
32. Huang S, Lee L, Hanson NB, Lenaerts C, Hoehn H, Poot M, Rubin CD, Chen DF, Yang CC, Juch H, et al. 2006. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 27: 558-567.
33. Hudson G, Chinnery PF. 2006. Mitochondrial DNA polymerase-g and human disease. Hum Mol Genet 15: R244-R252.
34. Hughes CR, Guasti L, Meimaridou E, Chuang CH, Schimenti JC, King PJ, Costigan C, Clark AJ, Metherell LA. 2012. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 122: 814-820.
35. Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N. 2002. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 16: 10-15.
36. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. 2004. For the Colorectal Cancer Study Group. Fecal DNAversus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714.
37. Jam K, Fox M, Crandall BF. 1999. RAPADILINO syndrome: A multiple malformation syndrome with radial and patellar aplasia. Teratology 60: 37-38.
38. Kato H, Toki T, Shimizu M, Shiozawa T, Fujii S, Nikaido T, Konishi I. 2003. A new proliferation marker, minichromosome maintenance protein 2, is associatedwith tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84: 24-30.
39. Kodani I, Osaki M, Shomori K, Araki K, Goto E, Ryoke K, Ito H. 2003. Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 32: 468-474.
40. Kruger S, Thorns C, Stocker W, Muller-Kunert E, Bohle A, Feller AC. 2003. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder. Eur Urol 43: 138-145.
41. Larizza L, Roversi G, Volpi L. 2010. Rothmund-Thomson syndrome. Orphanet J Rare Dis 5: 2.
42. Laskey RA. 2004. DNA and cancer. In DNA: Changing science and society (ed. Krude T), p. 88. Cambridge University Press, Cambridge.
43. Longley MJ, Clark S, YuWaiMan C, Hudson G, Durham SE, Taylor RW, Nightingale S, Turnbull DM, Copeland WC, Chinnery PF. 2006. Mutant POLG2 disrupts DNA polymerase g subunits and causes progressive external ophthalmoplegia. Am J Hum Genet 78: 1026-1034.
44. Madine MA, Swietlik M, Pelizon C, Romanowski P, Mills AD, Laskey RA. 2000. The roles of the MCM, ORC, and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struct Biol 129: 198-210.
45. Mandel H, Szargel R, Labay V, ElpelegO, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M, et al. 2001. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29: 337-341.
46. McGarry TJ, KirschnerMW. 1998. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93: 1043-1053.
47. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty T.D. 2001. Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer. Clin Cancer Res 7: 2712-2718.
48. Mills AD, Coleman N, Morris LS, Laskey RA, 2000. Detection of S phase cells in tissue sections by in situ DNA replication. Nat Cell Biol 2: 244-245.
49. Monnat RJ Jr. 2010. Human RECQ helicases: Roles in DNA metabolism, mutagenesis and cancer biology. Semin Cancer Biol 20: 329-339.
50. Muftuoglu M, Oshima J, von Kobbe C, Cheng WH, Leistritz DF, Bohr VA. 2008. The clinical characteristics of Werner syndrome: Molecular and biochemical diagnosis. Hum Genet 124: 369-377.
51. Mukherjee G, Muralidhar B, Bafna UD, Laskey RA, Coleman N. 2007. MCMimmunocytochemistry as a first line cervical screening test in developing countries: A prospective cohort study in a regional cancer centre in India. Br J Cancer 96: 1107-1111.
52. Musahl C, Holthoff HP, Lesch R, Knippers R. 1978. Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. Exp Cell Res 241: 260-264.
53. Oshima J, Martin GM, Hisama FM. 2012. Werner syndrome. In GeneReviews (ed. Pagon RA, et al.). University of Washington, Seattle.
54. Ozaki S, Zen Y, Inoue M. 2011. Biomarker expression in cervical intraepithelial neoplasia: Potential progression predictive factors for low-grade lesions. Hum Pathol 42: 1007-1012.
55. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, Hyland A, Todoro IT, Brooks JS, Bepler G. 2001. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19: 4259-4266.
56. Rhodes JM. 2000. Colorectal cancer screening in the UK: Joint position statement by the British Society of Gastroenterology, the Royal College of Physicians, and the Association of Coloproctology of Great Britain and Ireland. Gut 46: 746-748.
57. Rodins K, Cheale M, Coleman N, Fox SB. 2002. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: Relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 8: 1075-1081.
58. Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. 2001. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29: 342-344.
59. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips M-L, et al. 2008. Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev 17: 2855-2864.
60. Scholzen T, Gerdes J. 2000. The Ki-67 protein: From the known and the unknown. J Cell Physiol 182: 311-322.
61. Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook M, Marshall AE, Laskey RA, Miller R, Arends MJ, et al. 2003. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: Implications for the prediction of outcome in colorectal cancer. J Pathol 201: 187-197.
62. Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burne NG, Coleman N. 2005. Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: Applications in diagnostic neuropathology. Neuropathol Appl Neurobiol 31: 455-466.
63. Scott IS, Odell E, Chatrath P, Morris LS, Davies RJ, Vowler SL, Laskey RA, Coleman N. 2006. A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia. Br J Cancer 94: 1170-1175.
64. Shima N, Alcaraz A, Liachko I, Buske TR, Andrews CA, Munroe RJ, Hartford SA, Tye BK, Schimenti JC. 2007. A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet 39: 93-98.
65. Siitonen HA, Sotkasiira J, Biervliet M, Benmansour A, Capri Y, Cormier-Daire V, Crandall B, Hannula-Jouppi K, Hennekam R, Herzog D, et al. 2009. The mutation spectrum in RECQL4 diseases. Eur J Hum Genet 17: 151-158.
66. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, Wanrooij S, Garrido N, Comi G, Morandi L, et al. 2001. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 28: 223-231.
67. Stanley M. 2010. HPV-Immune response to infection and vaccination. Infect Agent Cancer 5: 19.
68. Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, Coleman N, Bullock N, Laskey RA, Hales CN, et al. 1999. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 354: 1524-1525.
69. Stoeber K, Tlsty RTD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH. 2001. DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027-2041.
70. Stoeber K, Swinn R, Prevost AT, de Clive-Lowe P, Halsall I, Dilworth SM, Marr J, Turner WH, Bullock N, Doble A, et al. 2002. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 94: 1071-1079.
71. Suomalainen A, Isohanni P. 2010. Mitochondrial DNA depletion syndromes-Many genes, common mechanisms. Neuromuscul Disord 20: 429-437.
72. Sznajer Y, Siitonen HA, Roversi G, Dangoisse C, Scaillon M, Ziereisen F, Tenoutasse S, Kestila M, Larizza L. 2008. Atypical Rothmund-Thomson syndrome in a patient with compound heterozygous mutations in RECQL4 gene and phenotypic features in RECQL4 syndromes. Eur J Pediatr 167: 175-181.
73. Tachibana KK, Gonzalez MA, Coleman N. 2005. Cell cycle control of DNA replication and its relevance to cancer pathology. J Pathol 205: 123-129.
74. Tada S, Li A, Maiorano D, Mechali M, Blow JJ. 2001. Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. Nat Cell Biol 3: 107-113.
75. Tambouret RH, Misdraji J, Wilbur DC. 2008. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch Pathol Lab Med 132: 918-925.
76. Todorov IT, Werness BA, Wang HO, Buddharaju LN, Todorova PD, Slocum HK, Brooks JS, Huberman JA. 1998. HsMCM2/BM28: A novel proliferation marker for human tumors and normal tissues. Lab Invest 78: 73-78.
77. Toschi L, Bravo R. 1988. Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol 107: 1623-1628.
78. Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. 2001. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 28: 211-212.
79. Vennos EM, Collins M, James WD. 1992. Rothmund-Thomson syndrome: Review of the world literature. J Am Acad Dermatol 27: 750-762.
80. Wang LL, Levy ML, Lewis RA, Chintagumpala MM, Lev D, Rogers M, Plon SE. 2001. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 102: 11-17.
81. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. 2001. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 27: 305-313.
82. White V, Scarpini C, Barbosa-Morais NL, Ikelle E, Carter S, Laskey RA, Miller R, Coleman N. 2009. Isolation of stoolderived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 18: 2006-2013.
83. Williams GH, Romanowski P, MillsAD, Morris L, Stoeber K, Marr J, Laskey RA, Coleman NC. 1998. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci 95: 14932-14937.
84. Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Dutta A. 2000. Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science 290: 2309-2312.
85. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 11: 174-183.
86. Young MJ, Longley MJ, Li FY, Kasiviswanathan R, Wong LJ, Copeland WC. 2011. Biochemical analysis of human POLG2 variants associated with mitochondrial disease. Hum Mol Genet 20: 3052-3066.